Literature DB >> 22036238

Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study.

Rafel Ramos1, Elisabet Balló, Jaume Marrugat, Roberto Elosua, Joan Sala, Maria Grau, Joan Vila, Bonaventura Bolíbar, Maria García-Gil, Ruth Martí, Francesc Fina, Eduardo Hermosilla, Magdalena Rosell, Miguel Angel Muñoz, Daniel Prieto-Alhambra, Miquel Quesada.   

Abstract

INTRODUCTION AND
OBJECTIVES: Information in primary care databases can be useful in research, but the validity of these data needs to be evaluated. We sought to analyze the validity of the data used in the EMMA study based on data from the Information System for the Development of Research in Primary Care.
METHODS: We compared the prevalence of cardiovascular risk factors observed in EMMA-hypertension, diabetes, hypercholesterolemia (and its treatments), obesity, and smoking-with equivalent data from the Registre Gironí del Cor (REGICOR), a population-based study that uses standardized methodology, in 2000. We also compared the incidence rates of vascular diseases and its association with these risk factors in a 5-year follow-up.
RESULTS: We analyzed data from 34 823 participants included in EMMA and 2540 REGICOR2000 study participants aged 35 to 74. The prevalence of risk factors did not differ significantly between the 2 studies, except for the prevalence of former smokers in men, which was higher in REGICOR2000 (24.7% [95% confidence interval, 23.9%-25.5%] vs 30.1% [95% confidence interval, 27.1%-33.1%]), and the proportion of patients with lipid-lowering and antihypertensive therapy, which was higher in EMMA (46.9% vs 32.7% and 8.7% vs 6.3%, respectively). There were no differences between the 2 studies when comparing the incidence of vascular diseases (2.1% in both studies in men and 1.18% [95% confidence interval, 0.7%-1.7%] in REGICOR2000 vs 0.75% [95% confidence interval, 0.64%-0.87%] in EMMA in women) and its association with risk factors.
CONCLUSIONS: The prevalence of cardiovascular risk factors and their association with the incidence of vascular disease observed in the EMMA study are consistent with those observed in an epidemiological population-based study with a standardized methodology.
Copyright © 2011 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22036238     DOI: 10.1016/j.recesp.2011.07.017

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  42 in total

1.  Burden of pelvis fracture: a population-based study of incidence, hospitalisation and mortality.

Authors:  D Prieto-Alhambra; F F Avilés; A Judge; T Van Staa; X Nogués; N K Arden; A Díez-Pérez; C Cooper; M K Javaid
Journal:  Osteoporos Int       Date:  2012-02-04       Impact factor: 4.507

2.  Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance.

Authors:  K Berencsi; A Sami; M S Ali; K Marinier; N Deltour; S Perez-Gutthann; L Pedersen; P Rijnbeek; J Van der Lei; F Lapi; M Simonetti; C Reyes; M C J M Sturkenboom; D Prieto-Alhambra
Journal:  Osteoporos Int       Date:  2019-11-06       Impact factor: 4.507

3.  Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records.

Authors:  Marc Casajuana; Maria Giner-Soriano; Albert Roso-Llorach; Cristina Vedia; Concepció Violan; Rosa Morros
Journal:  Eur J Health Econ       Date:  2018-02-20

4.  Risk of colorectal cancer in users of bisphosphonates: analysis of population-based electronic health records.

Authors:  Gemma Ibáñez-Sanz; Elisabet Guinó; Caridad Pontes; Rosa Morros; Luisa C de la Peña-Negro; Mª Ángeles Quijada-Manuitt; Victor Moreno
Journal:  Eur J Epidemiol       Date:  2019-11-16       Impact factor: 8.082

5.  Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.

Authors:  Bogdan Vlacho; Maria Giner-Soriano; Edurne Zabaleta-Del-Olmo; Albert Roso-Llorach; Ana García-Sangenís; Rosa Morros-Pedrós
Journal:  Eur J Clin Pharmacol       Date:  2017-07-19       Impact factor: 2.953

6.  The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study.

Authors:  C Reyes; P Estrada; X Nogués; P Orozco; C Cooper; A Díez-Pérez; F Formiga; J González-Macías; J G Mácias; D Prieto-Alhambra
Journal:  Osteoporos Int       Date:  2014-03-28       Impact factor: 4.507

7.  Do individuals with autoimmune disease have increased risk of subclinical carotid atherosclerosis and stiffness?

Authors:  Maria Del Mar Vila; Beatriz Remeseiro; Laura Igual; Roberto Elosua; Rafel Ramos; Jose Manuel Valdivielso; Ruth Martí-Lluch; Jaume Marrugat; Maria Grau
Journal:  Hypertens Res       Date:  2021-04-08       Impact factor: 3.872

8.  "Burden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based study".

Authors:  Aina Pagès-Castellà; Cristina Carbonell-Abella; Francesc Fina Avilés; Maite Alzamora; Jose Miguel Baena-Díez; Daniel Martínez Laguna; Xavier Nogués; Adolfo Díez-Pérez; Daniel Prieto-Alhambra
Journal:  BMC Musculoskelet Disord       Date:  2012-05-28       Impact factor: 2.362

9.  Risk Diagrams Based on Primary Care Electronic Medical Records and Linked Real-Time PCR Data to Monitor Local COVID-19 Outbreaks During the Summer 2020: A Prospective Study Including 7,671,862 People in Catalonia.

Authors:  Marti Catala; Ermengol Coma; Sergio Alonso; Enrique Álvarez-Lacalle; Silvia Cordomi; Daniel López; Francesc Fina; Manuel Medina-Peralta; Clara Prats; Daniel Prieto-Alhambra
Journal:  Front Public Health       Date:  2021-07-05

10.  Comparison of the information provided by electronic health records data and a population health survey to estimate prevalence of selected health conditions and multimorbidity.

Authors:  Concepción Violán; Quintí Foguet-Boreu; Eduardo Hermosilla-Pérez; Jose M Valderas; Bonaventura Bolíbar; Mireia Fàbregas-Escurriola; Pilar Brugulat-Guiteras; Miguel Ángel Muñoz-Pérez
Journal:  BMC Public Health       Date:  2013-03-21       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.